CSL Limited (CSLLY) Stock Price & Analysis
CSL Limited (CSLLY) is trading at USD 34.53, up 0.61% today, as of October 23, 2026 at 15:23 UTC (US market open; quotes may be delayed), according to Nexqual market data.
CSLLY last closed at USD 34.32; today's session has ranged USD 34.53–34.53 on volume of 800 shares. Market capitalization is $66.28B, with a 52-week range of USD 16.01–35.64 (OQX). Source: Nexqual, retrieved October 23, 2026 at 16:40 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CSLLY.md
Key facts (CSLLY)
- Analysts: Hold (mean 3.00 on a 1–5 scale) (1 analysts), mean target USD 34 (range 34–34).
- Total return with dividends: 1Y -0.4% vs S&P 500 +14.6%; 5Y -34.7% vs S&P 500 +77.3%.
- Next earnings: 2026-08-17, EPS estimate USD —, revenue estimate $0K.
Analysts (CSLLY)
Consensus Hold (mean 3.00 on a 1–5 scale), 1 analysts; mean target USD 34 (low 34, high 34).
Total return (dividends reinvested) (CSLLY)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -0.4% | -34.7% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | -0.4% | -8.2% |
| Volatility (annualized) | 43.6% | 31.7% |
| Max drawdown | -53.5% (Oct 2025→Jun 2026) | -68.8% (Nov 2021→Jun 2026) |
CSLLY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Jun 2027) | $1.54 | $1.57 | -2.1% | $15.76B | 1 |
| Next fiscal year (ends Jun 2028) | $1.68 | $0.00 | — | $16.32B | 1 |
Key Statistics (as of October 23, 2026 at 16:40 UTC)
| Price | USD 34.53 |
|---|---|
| Change | ▲ 0.61% (up) |
| Previous Close | USD 34.32 |
| Open | USD 34.53 |
| Day Range | USD 34.53 – 34.53 |
| 52-Week Range | USD 16.01 – 35.64 |
| Volume | 800 shares |
| Market Cap | $66.28B |
| Exchange | OQX |
Technical Analysis (CSLLY)
Nexqual's technical model rates CSLLY "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of October 23, 2026 at 16:40 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 68.92 (neutral) |
| vs SMA50 | Above (USD 31.25) |
| MACD | 1.03 (positive) |
Analyst Ratings (CSLLY)
Wall Street analysts rate CSLLY "Hold" based on 1 analysts, with a mean price target of USD 34 (range USD 34–34), per Nexqual as of October 23, 2026 at 16:40 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 34 |
| High Target | USD 34 |
| Low Target | USD 34 |
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (CSLLY)
| Next Earnings Date | 2026-08-17 |
|---|
Source: Nexqual, October 23, 2026 at 16:40 UTC.
Financials & Fundamentals (CSLLY)
| Total Revenue | $15.80B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.50% |
| Gross Margin | +51.12% |
| Operating Margin | +21.49% |
| Profit Margin | -16.33% |
| ROE | -15.83% |
| Debt / Equity | 0.67 |
| Current Ratio | 2.21 |
| Total Cash | $1.51B |
| Total Debt | $10.90B |
Source: Nexqual, October 23, 2026 at 16:40 UTC.
Financial Health Score (CSLLY)
Nexqual rates CSL Limited's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 16:40 UTC.
| Growth | Mixed — Revenue +1.5% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 51%, operating 21% (last 12 months) |
| Balance Sheet | Strong — $1.51B cash vs $10.9B debt |
| Cash Flow | Solid — Operating cash flow $3.51B (TTM) |
| Efficiency | Critical — ROE -16%, ROA 7.3% |
Ownership (CSLLY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.01% |
| Shares Outstanding | 1.92B |
| Float | 1.91B |
Source: Nexqual, October 23, 2026 at 16:40 UTC.
Leadership (CSLLY)
CSL Limited is led by Gordon Naylor BEng (Hons), C.P.A., DipCompSc, CEO, MD & Executive Director, per Nexqual as of October 23, 2026 at 16:40 UTC.
| CEO, MD & Executive Director | Gordon Naylor BEng (Hons), C.P.A., DipCompSc |
|---|---|
| Chief Financial Officer | Ken Lim |
| Executive VP & COO | Mary Oates |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARGX | argenx SE | USD 879.29 | ▲ 0.4% |
| MRNA | Moderna, Inc. | USD 205.98 | ▲ 1.65% |
| REGN | Regeneron Pharmaceuticals, Inc. | USD 808 | ▼ 1.35% |
| ONC | BeOne Medicines Ltd. | USD 376.52 | ▼ 1.5% |
| RVMD | Revolution Medicines, Inc. | USD 188.72 | ▲ 0.55% |
| RPRX | Royalty Pharma plc | USD 63.63 | ▼ 0.2% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt